Management of High Risk Non-Muscle Invasive Bladder Cancer.
DOI:
https://doi.org/10.54212/27068048.v6i1.73Keywords:
Importancia de la re-resección, Uso juicioso de biomarcadores, BCG es la primera líneaAbstract
Non-muscle invasive bladder cancer is a common malignancy. Among all patients diagnosed with bladder cancer, 75% present as non-invasive and 70% recur after transurethral resection of bladder tumor (TURBT), usually within 3 years.1 Unfortunately, 15-20% progress to muscle invasive disease. Progression is more likely among patients with significant risk factors: higher stage, grade, increased size, history of prior recurrence and multiplicity and presence of carcinoma in situ. These risk factors form the basis for the American Urological Association guidelines risk categories, by which all surveillance, diagnosis and treatment are recommended.
Downloads
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
https://doi.org/10.3322/caac.21332 DOI: https://doi.org/10.3322/caac.21332
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. The Journal of urology 2016;196:1021-9. https://doi.org/10.1016/j.juro.2016.06.049 DOI: https://doi.org/10.1016/j.juro.2016.06.049
Linder BJ, Boorjian SA, Cheville JC, et al. The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? The Journal of urology 2013;190:1692-6. https://doi.org/10.1016/j.juro.2013.05.040 DOI: https://doi.org/10.1016/j.juro.2013.05.040
Herr HW. Role of Repeat Resection in Non-Muscle-Invasive Bladder Cancer. J Natl Compr Canc Netw 2015;13:1041-6.
https://doi.org/10.6004/jnccn.2015.0123 DOI: https://doi.org/10.6004/jnccn.2015.0123
Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. The Journal of urology 2008;179:2164-9. https://doi.org/10.1016/S0022-5347(08)61800-5
https://doi.org/10.1016/j.juro.2008.01.105 DOI: https://doi.org/10.1016/j.juro.2008.01.105
Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of non muscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 2009;124:2899-904.
https://doi.org/10.1002/ijc.24258 DOI: https://doi.org/10.1002/ijc.24258
Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209-16. https://doi.org/10.1046/j.1464-410x.2001.02306.x DOI: https://doi.org/10.1046/j.1464-410x.2001.02306.x
Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. The Journal of urology 2000;163:1124-9.
https://doi.org/10.1016/S0022-5347(05)67707-5 DOI: https://doi.org/10.1016/S0022-5347(05)67707-5
https://doi.org/10.1097/00005392-200004000-00014 DOI: https://doi.org/10.1097/00005392-200004000-00014
Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. European urology 2013;63:462-72. https://doi.org/10.1016/j.eururo.2012.10.039 DOI: https://doi.org/10.1016/j.eururo.2012.10.039
Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? The Journal of urology 2001;166:1296-9. https://doi.org/10.1016/S0022-5347(05)65756-4 DOI: https://doi.org/10.1016/S0022-5347(05)65756-4
Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl 1995;172:33-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Angela B. Smith
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
